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DSSHDUDQFHRIFDQFHU$OWKRXJK WKHVSHFL¿FLW\ IRU
these responses is high, typically only 5-20% of pa-
tients demonstrate a response to any given antigen, 
which has limited the usefulness of single antigen 
responses as biomarkers. The recent development 
of protein microarrays may offer an ideal tool for 
screening for immune response to tumor antigens. 
These arrays offer the advantage that hundreds to 
thousands of different proteins can be printed and 
screened simultaneously and only require a few 
microliters of serum per assay.
Prof. LaBaer’s group (Harvard Institute of Pro-
teomics) has developed a novel method for produ-
cing protein microarrays called nucleic acid progra-
mmable protein arrays (NAPPA) that avoids the need 
to express and purify the proteins by substituting the 
printing of cDNAs on the arrays, which are then 
transcribed and translated in situ as needed at the 
time of the assay. NAPPA has been used successfu-
lly to map the pairwise protein interactions of the 
human DNA replication complex. Here, we propose 
adapting the NAPPA protein microarray technology 
IRUXVHLQWKHUDSLGDQGHI¿FLHQWVFUHHQLQJRIVHUD
from cancer patients for antibodies to 1000 known 
and potential tumor antigens in a multiplex format 
in order to better characterize the immune response 
to known tumor antigens, identify new informative 
tumor antigens and evaluate the value of using pat-
terns of tumor antigen immune responses as biomar-
kers in Colorectal Cancer.  For the validation of the 
possible biomarkers found in 20 different patients 
SUH	SRVWFKHPRWKHUDS\FXUUHQWO\ZHDUHXVLQJ
iFISH and SNPs approaches with the main goal to 
correlate genomics and functional proteomics. 
Introduction
3URVWDWHVSHFL¿FDQWLJHQ36$VHUXPPHDVXUH-
ment in combination with a digital rectal examinati-
on (DRE) and transrectal ultrasound-guided biopsy 
(TURS) is currently the gold standard for prostate 
cancer (PCa) screening in Europe [1]. Nevertheless, 
36$DQG'5(ODFNVLJQL¿FDQWVSHFL¿FLW\DQGELRSV\
lacks ideal sensitivity (12-30% false negatives) [2, 
3]. Therefore additional biomarkers are needed to 
supplement or potentially replace the currently used 
diagnostic techniques. As the secreted products from 
both, normal prostate epithelial cells as well as PCa 
cells, can be detected in the urine of men, their use as 
DSUR[LPDOERG\ÀXLGWRGHWHFW3&DLVYHU\DWWUDFWLYH
since they could be the best compromise between 
a minimal invasive technique accepted by a wider 
range of the male population and the possibility to 
obtain enough cells for a correct diagnosis [4, 5]. 
Objective
:HVRXJKWWRGHWHUPLQHDSURWHRPLFSUR¿OHLQ
urine able to distinguish between the presence and 
absence of PCa.
0DWHULDO	0HWKRGV
:HXVHGDFRPELQDWLRQRISURWHRPLF WHFKQRO-
ogies in aged matched post-Digital Rectal Exam 
(DRE) urine supernatants specimens to identify dif-
ferentially expressed proteins in patients with PCa. 
)LUVWO\ZHGHSOHWHGKLVWRORJLFDO FRQ¿UPHG3&D
urine samples and 9 control samples (age-matched 
patients with the typical background of benign pros-
WDWHKLSHUSODV\%3+DWURSK\DQGFKURQLFLQÀDP-
mation) using ProteoMiner (BioRad), a novel deple-
tion technique that reduces the level of the most 
abundant species, while strongly concentrating the 
more dilute and rare ones. Then, Two-dimensional 
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gel-based proteomic approach (2D-DIGE) coupled 
with matrix assisted laser desorption/ionization ti-
PHRIÀLJKWPDVVVSHFWURPHWU\0$/',72)06
and database mining experiment were performed to 
identify novel biomarkers of PCa in urine. Finally, 
we validated the candiadate biomarkers using Multi-
ple Reaction Monitoring (MRM)-based assays, con-
ducted by Liquid chromatography in conjunction 
with triple quadrupole mass spectrometry (LC-MS/
MS) in a bigger cohort of urine samples.
Results
:HLGHQWL¿HGDSURWHRPLFSUR¿OHRISRWHQ-
tial biomarkers (16 down and 10 up-expressed) 
for the detection of PCa in urine. Ingenuity pat-
hways analysis (IPA) showed that the majority of 
these proteins are secreted components of several 
ZHOONQRZQIXQFWLRQDORIFDQFHUDQGLQÀDPPDWL-
RQQHWZRUNV OLNH1)Ʉ%3'*)%ȕDQG36$:H
performed MRM-based assays for 15 candidate 
biomarkers to quantify these in a sample set of 50 
urine supernatants (Figure 1).
Figure 1. 3URWHLQ LGHQWL¿FDWLRQE\SURWHRPLF FRPSDUDWLYH DQDO\VLV $3URWHR0LQHUGHSOHWLRQ WHFKQLTXHRYHUYLHZ %
2D-DIGE experiment design, comparison of  9 urine PCa samples against 9 urine control samples. (C) Example of a 
representive gel of the DIGE experiment. (D) Example of up-expressed spot in PCa samples. (E) IPA network interaction 
RIRYHUH[SUHVVHGSURWHLQVSRWVUHG¿JXUHVDQGXQGHUH[SUHVVHGSURWHLQVSRWVJUHHQ¿JXUHV)050WUDQVLWLRQVRID
WU\SWLFSHSWLGHGHULYHGIURPRQHRIWKHFDQGLGDWHELRPDUNHUSURWHLQV*050EDVHGDEVROXWHTXDQWL¿FDWLRQRIDSHSWLGH
abundance using a labeled synthetic peptide as internal standard.
Conclusions
These data demonstrate the ability of proteo-
mic analyses to reveal novel biomarkers for PCa 
in urine, an important step forward in advancing 
accurate diagnosis which is currently the bottleneck 
for the ability to cure patients from PCa. MRM is 
emerging as a technology that ideally complements 
the discovery capabilities of shotgun strategies by 
LWV XQLTXH SRWHQWLDO IRU UHOLDEOH TXDQWL¿FDWLRQ RI
analytes of low abundance in complex mixtures, 
such urine samples[6]. These biomarkers could be 
used to develop a a simple diagnostic test (probably 
similar to the ELISA, either multiplex or strips, 
reactive to the 4-5 molecules most representative of 
WKHGLIIHUHQWLDOSUR¿OHWREHXVHGLQWKHKRVSLWDODQG
outpatient routines.
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Introduction 
Osteoarthritis (OA) is the most common rheu-
matic pathology, characterized mainly by cartilage 
degradation [1]. Despite its high prevalence, the 
diagnosis methods currently available are limited 
and lacked of sensitivity. Therefore, there is a con-
siderable interest pointed in the characterization of 
QHZVSHFL¿F2$ELRPDUNHUVLQELRORJLFDOÀXLGV,Q
this work we set up a nLC-MALDI-MS method for 
OA biomarker search in complex mixtures, with the 
aim of obtaining a standardized protocol for serum 
DQGV\QRYLDOÀXLG6)SURWHLQSUR¿OLQJ
Methods
a) Sample preparation and immunodepletion:
Serum and SF samples were obtained from OA pa-
tients and control donors. Prior to protein depletion, 
SF was treated with hyaluronidase. The 20 most abun-
NanoLC/mass spectrometry-based proteomic analysis of serum and synovial 
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dant proteins were removed from crude serum and SF 
using the Immunodepletion column ProteoPrep® 20 
(Figure 1), according to manufacturer’s instructions 
(Sigma Aldrich). Depletion of abundant proteins was 
checked by SDS-PAGE separation of the proteins and 
LGHQWL¿FDWLRQ LQD0$/',72)72)V\VWHP
(ABI). For both serum and SF depleted samples, pro-
tein concentration was determined using a nanoDrop 
LQVWUXPHQW)LVKHU7KHUPR6FLHQWL¿F86$
b) Pre-fractioning of the samples: For serum sam-
ples, digestion of the depleted fractions was done 
with trypsin, and the peptides obtained were frac-
tionated by strong cation exchange (SCX) liquid 
chromatography in a HP 1200 system (Agilent), 
using a  PolySulfoethyl column (PolyLC). SF pro-
teins were separated by SDS-PAGE, using 10% 
acrylamide gels. The gel lanes were divided into 12 
sections, excised and proteins were in-gel digested 
with trypsin following standard procedures. 
